Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Keith J, August"'
Autor:
Carolyn R. Bates, Renee M. Gilbert, Kelsey M. Dean, Keith J. August, Christie A. Befort, Shallyn Ward, Mary Gibson, Meredith L. Dreyer Gillette
Publikováno v:
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Lack of diversity in participants throughout the research process limits the generalizability of findings and may contribute to health disparities. There are unique challenges to recruitment of families to pediatric cancer researc
Externí odkaz:
https://doaj.org/article/494a74d7788a4b029ca15929164bb59c
Autor:
Rajen Mody, Carl H June, Michael R Verneris, Stephan A Grupp, Keith J August, André Baruchel, Shannon L Maude, Peter Bader, Stella M Davies, John E Levine, Michael A Pulsipher, Andrew C Dietz, Susana Rives, G Douglas Myers, Jochen Buechner, Theodore W Laetsch, Henrique Bittencourt, Michael W Boyer, Barbara De Moerloose, Muna Qayed, Christine L Phillips, Timothy A Driscoll, Krysta Schlis, Patricia A Wood, Lan Yi, Mimi Leung, Lamis K Eldjerou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T cell therapy, has demonstrated efficacy in children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) in two multicenter phase 2 trials (Clinica
Externí odkaz:
https://doaj.org/article/77ef91a4ad514631aed50eef2972200b
Autor:
Andrew M. Stein, Stephan A. Grupp, John E. Levine, Theodore W. Laetsch, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, Bruce L. Levine, Lori Tomassian, Sweta Shah, Mimi Leung, Pai‐Hsi Huang, Rakesh Awasthi, Karen Thudium Mueller, Patricia A. Wood, Carl H. June
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 5, Pp 285-295 (2019)
Tisagenlecleucel is a chimeric antigen receptor–T cell therapy that facilitates the killing of CD19+ B cells. A model was developed for the kinetics of tisagenlecleucel and the impact of therapies for treating cytokine release syndrome (tocilizumab
Externí odkaz:
https://doaj.org/article/e1eac9e64fa4445bbb240eabb2a86beb
Autor:
Weijie Li, Keith J August, Erin M Hall, Dwight E Yin, Rakesh K Goyal, Atif A Ahmed, Grace S Mitchell, Shawn D St. Peter, Terrie G Flatt, Ibrahim A Ahmed, Richard J Hendrickson, G Doug Myers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Background Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy, has demonstrated durable efficacy and a manageable safety profile in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic le
Externí odkaz:
https://doaj.org/article/ebd8b85ed1f64889854a9550a505497f
Autor:
David T. Teachey, Meenakshi Devidas, Brent L. Wood, Zhiguo Chen, Robert J. Hayashi, Michelle L. Hermiston, Robert D. Annett, J. Hunter Archer, Barbara L. Asselin, Keith J. August, Steve Y. Cho, Kimberly P. Dunsmore, Brian T. Fisher, Jason L. Freedman, Paul J. Galardy, Paul Harker-Murray, Terzah M. Horton, Alok I. Jaju, Allison Lam, Yoav H. Messinger, Rodney R. Miles, Maki Okada, Samir I. Patel, Eric S. Schafer, Tal Schechter, Neelam Singh, Amii C. Steele, Maria Luisa Sulis, Sarah L. Vargas, Stuart S. Winter, Charlotte Wood, Patrick Zweidler-McKay, Catherine M. Bollard, Mignon L. Loh, Stephen P. Hunger, Elizabeth A. Raetz
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 19
PURPOSE To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III clinical trial AALL1231, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ad77077f78bd85acc4f42ec987b359a
https://pubmed.ncbi.nlm.nih.gov/35271306
https://pubmed.ncbi.nlm.nih.gov/35271306
Autor:
Robert J. Hayashi, Michelle L. Hermiston, David T. Teachey, Meenakshi Devidas, Brent L. Wood, Zhiguo Chen, Robert D Annett, Barbara L Asselin, Keith J August, Steve Y Cho, Kimberly P. Dunsmore, Jason L. Freedman, Paul J. Galardy, Paul Harker-Murray, Terzah M. Horton, Alok I Jaju, Allison Lam, Yoav H. Messinger, Rodney R. Miles, Maki Okada, Samir I Patel, Eric S Schafer, Tal Schechter-Finkelstein, Kristin A. Shimano, Neelam Singh, Amii C. Steele, Maria Luisa Sulis, Sarah L Vargas, Stuart S. Winter, Charlotte Wood, Patrick A Zweidler-McKay, Mignon L. Loh, Stephen P. Hunger, Elizabeth A. Raetz, Catherine M Bollard, Carl Allen
Publikováno v:
Blood. 140:6387-6389
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbbe73dd1fbf587c56eaa82c57116fa3
https://doi.org/10.1182/blood-2022-159694
https://doi.org/10.1182/blood-2022-159694
Autor:
Van T Huynh, Sonia Morales, Anurag K. Agrawal, Christine L. Phillips, Keith J August, Erin Guest, Beth Apsel Winger, Catherine Aftandilian, Janel R. Long-Boyle, Kirsten Kasper, Keri Zabokrtsky, Carol Hwang Lin
Publikováno v:
Blood. 140:8893-8895
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7281e07c2b0efed377f30acb7416ec7
https://doi.org/10.1182/blood-2022-159255
https://doi.org/10.1182/blood-2022-159255
Autor:
Shannon L. Maude, Patricia A. Wood, Tetiana Taran, Mimi Leung, Sweta S. Shah, Lori Tomassian, Carl H. June, Bruce L. Levine, Abhijit Chakraborty, Denise Sickert, Andrew M. Stein, Rakesh Awasthi, Jason Hamilton, Keith J. August, Michael W. Boyer, Michael A. Pulsipher, Theodore W. Laetsch, John E. Levine, Stephan A. Grupp, Edward Waldron, Karen Thudium Mueller
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d26112761ad0dea9547df85ecdd32fd
https://doi.org/10.1158/1078-0432.22468554.v1
https://doi.org/10.1158/1078-0432.22468554.v1
Autor:
Shannon L. Maude, Patricia A. Wood, Tetiana Taran, Mimi Leung, Sweta S. Shah, Lori Tomassian, Carl H. June, Bruce L. Levine, Abhijit Chakraborty, Denise Sickert, Andrew M. Stein, Rakesh Awasthi, Jason Hamilton, Keith J. August, Michael W. Boyer, Michael A. Pulsipher, Theodore W. Laetsch, John E. Levine, Stephan A. Grupp, Edward Waldron, Karen Thudium Mueller
Purpose:Tisagenlecleucel is an anti-CD19 chimeric antigen receptor (CAR19) T-cell therapy approved for the treatment of children and young adults with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL).Patients and Methods:We evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2966852df65c2babfb4fccdcb3c7560
https://doi.org/10.1158/1078-0432.c.6526989.v1
https://doi.org/10.1158/1078-0432.c.6526989.v1
Autor:
Andy Warren, Michael A. Pulsipher, Theodore W. Laetsch, Stephen J. Schuster, G. Doug Myers, Peter Borchmann, John E. Levine, Michael Boyer, Edmund K. Waller, Edward Waldron, Stephan A. Grupp, Bernd Potthoff, Karen Thudium Mueller, Andrea Chassot-Agostinho, Ulrich Jaeger, Stephen Ronan Foley, Constantine S. Tam, Rakesh Awasthi, Keith J. August, Shannon L. Maude, Fraser McBlane
Publikováno v:
Blood Advances. 5:4980-4991
Tisagenlecleucel is indicated for pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL). The tisagenlecleucel chimeric antigen r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c056580c860ba6ef2dd3282aa8e3b47
https://doi.org/10.1182/bloodadvances.2020003844
https://doi.org/10.1182/bloodadvances.2020003844